Your browser doesn't support javascript.
loading
Prevalence and Predictors of Persistent Human Immunodeficiency Virus Viremia and Viral Rebound After Universal Test and Treat: A Population-Based Study.
Grabowski, M Kate; Patel, Eshan U; Nakigozi, Gertrude; Ssempijja, Victor; Ssekubugu, Robert; Ssekasanvu, Joseph; Ndyanabo, Anthony; Kigozi, Godfrey; Nalugoda, Fred; Gray, Ronald H; Kalibbala, Sarah; Serwadda, David M; Laeyendecker, Oliver; Wawer, Maria J; Chang, Larry W; Quinn, Thomas C; Kagaayi, Joseph; Tobian, Aaron A R; Reynolds, Steven J.
Afiliação
  • Grabowski MK; Department of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
  • Patel EU; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
  • Nakigozi G; Rakai Health Sciences Program, Entebbe, Uganda.
  • Ssempijja V; Department of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
  • Ssekubugu R; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
  • Ssekasanvu J; Rakai Health Sciences Program, Entebbe, Uganda.
  • Ndyanabo A; Rakai Health Sciences Program, Entebbe, Uganda.
  • Kigozi G; Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Sponsored by the National Cancer Institute, Bethesda, Maryland, USA.
  • Nalugoda F; Rakai Health Sciences Program, Entebbe, Uganda.
  • Gray RH; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
  • Kalibbala S; Rakai Health Sciences Program, Entebbe, Uganda.
  • Serwadda DM; Rakai Health Sciences Program, Entebbe, Uganda.
  • Laeyendecker O; Rakai Health Sciences Program, Entebbe, Uganda.
  • Wawer MJ; Rakai Health Sciences Program, Entebbe, Uganda.
  • Chang LW; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
  • Quinn TC; Rakai Health Sciences Program, Entebbe, Uganda.
  • Kagaayi J; Rakai Health Sciences Program, Entebbe, Uganda.
  • Tobian AAR; Rakai Health Sciences Program, Entebbe, Uganda.
  • Reynolds SJ; Makerere University School of Public Health, Kampala, Uganda.
J Infect Dis ; 223(7): 1150-1160, 2021 04 08.
Article em En | MEDLINE | ID: mdl-33471100
BACKGROUND: There are limited data on individual human immunodeficiency virus (HIV) viral load (VL) trajectories at the population-level after the introduction of universal test and treat (UTT) in sub-Saharan Africa. METHODS: Human immunodeficiency virus VLs were assessed among HIV-positive participants through 3 population-based surveys in 4 Ugandan fishing communities surveyed between November 2011 and August 2017. The unit of analysis was a visit-pair (2 consecutive person-visits), which were categorized as exhibiting durable VL suppression, new/renewed VL suppression, viral rebound, or persistent viremia. Adjusted relative risks (adjRRs) and 95% confidence intervals (CIs) of persistent viremia were estimated using multivariate Poisson regression. RESULTS: There were 1346 HIV-positive participants (n = 1883 visit-pairs). The population-level prevalence of durable VL suppression increased from 29.7% to 67.9% during UTT rollout, viral rebound declined from 4.4% to 2.7%, and persistent viremia declined from 20.8% to 13.3%. Younger age (15-29 vs 40-49 years; adjRR = 1.80; 95% CI = 1.19-2.71), male sex (adjRR = 2.09, 95% CI = 1.47-2.95), never being married (vs currently married; adjRR = 1.88, 95% CI = 1.34-2.62), and recent migration to the community (vs long-term resident; adjRR = 1.91, 95% CI = 1.34-2.73) were factors associated with persistent viremia. CONCLUSIONS: Despite increases in durable VL suppression during roll out of UTT in hyperendemic communities, a substantial fraction of the population, whose risk profile tended to be younger, male, and mobile, remained persistently viremic.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Viremia / Infecções por HIV / Soropositividade para HIV / Fármacos Anti-HIV Tipo de estudo: Diagnostic_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Female / Humans / Male / Middle aged País/Região como assunto: Africa Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Viremia / Infecções por HIV / Soropositividade para HIV / Fármacos Anti-HIV Tipo de estudo: Diagnostic_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Female / Humans / Male / Middle aged País/Região como assunto: Africa Idioma: En Ano de publicação: 2021 Tipo de documento: Article